Effect of mirtazapine on weight and metabolic profile among psychiatric patients: A prospective, observational study from South India
DOI:
https://doi.org/10.30834/KJP.37.1.2024.385Keywords:
Mirtazapine, weight gain, metabolic, tertiary care, IndiaAbstract
Background: Treatment with mirtazapine is reported to cause weight gain and adverse metabolic profile in several populations. Limited information is available regarding the metabolic adverse effects of mirtazapine in the Indian population. This study aims to compare the weight and metabolic profile of patients on mirtazapine at baseline and after six months of treatment in a tertiary care Indian setting. Methodology: This hospital-based, observational study was conducted in a tertiary care teaching institute in South India. Forty patients prescribed mirtazapine for various psychiatric disorders were included. Weight, body mass index, lipid profile, blood sugar, and HbA1c values were compared at baseline and after six months of treatment. Descriptive statistics used included mean and standard deviation (SD). Results: Statistically significant increase in mean weight (0.97 kg, SD - 2.2; p = 0.008), mean BMI, mean HbA1C (0.1, SD - 0.21; p = 0.007), and mean total cholesterol (6.6 mg/dl, SD - 13.5; p = 0.005) was observed after six months of treatment with mirtazapine. Conclusion: The study demonstrates the importance of close monitoring of patients who are started on mirtazapine to identify and treat metabolic deregulation promptly. Long-term, controlled studies in larger samples are needed to arrive at meaningful conclusions.
Downloads
References
Baptista T, Zárate J, Joober R, Colasante C, Beaulieu S, Páez X, Hernández L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5:279-99.
Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 2013;15:PCC.13r01525.
Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-85.
Jilani TN, Gibbons JR, Faizy RM, Saadabadi A. Mirtazapine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lechner-Schoner T, Strauss R, Enget J, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006;67:421-4.
Ranjbar S, Pai NB, Deng C. The association of antidepressant medication and body weight gain. Online J Health Allied Sci 2013;12:1-9.
Vijayakumar G, Manghat S, Vijayakumar R, Simon L, Scaria LM, Vijayakumar A, et al. Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort. BMC Public Health 2019;19:140. Available from: https://doi.org/10.1186/s12889-019-6445-6.
Harikrishnan S, Sarma S, Sanjay G, Jeemon P, Krishnan MN, Venugopal K, et al. Prevalence of metabolic syndrome and its risk factors in Kerala, South India: Analysis of a community based cross-sectional study. PLoS One 2018; 13(3) : e0192372. Available from: doi: 10.1371/journal.pone.0192372.
India State-Level Disease Burden Initiative Mental Disorders Collaborators. The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990-2017. Lancet Psychiatry 2020;7:148-61. Available from: https://doi.org/10.1016/S2215-0366(19)30475-4.
Mazereel V, Detraux J, Vancampfort D, van Winkel R, De Hert M. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol 2020;11:573479. Available from: doi: 10.3389/fendo.2020.573479.
Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes 2018;11:427-38. Available from: doi:10.2147/DMSO.S171365.
Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry 2015;37:46-8.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Routledge; 1988.
Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ 2018;361:k1951. Available from: https://doi.org/10.1136/bmj.k1951.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72.
Song HR, Bahk W-M, Woo YS, Jeong J-H, Kwon Y-J, Seo JS, et al. Efficacy and tolerability of generic mirtazapine (mirtax) for major depressive disorder: multicenter, open-label, uncontrolled, prospective study. Clin Psychopharmacol Neurosci 2015;13:144-9. Available from: doi: 10.9758/cpn.2015.13.2.144.
Hennings JM, Heel S, Lechner K, Uhr M, Dose T, Schaaf L,et al. Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men. JCI Insight 2019;4:e123786. Available from: doi: 10.1172/jci.insight.123786.
Song HR, Woo YS, Wang H-R, Shim I-H, Jun T-Y, Bahk W-M. Does mirtazapine interfere with naturalistic diabetes treatment? J Clin Psychopharmacol 2014;34:588-94.
Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002;35:220-5.
Chao G, Zhu Y, Chen L. Role and risk factors of glycosylated hemoglobin levels in early disease screening. J Diabetes Res 2021;2021:6626587. Available from: doi: 10.1155/2021/6626587.
Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003;64:883-9.
Moreira FP, Jansen K, Cardoso TA, et al. Metabolic syndrome and psychiatric disorders: a population-based study. Braz J Psychiatry. 2019;41(1):38-43.
Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci 2018;20:63-73.
Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-53.
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459-525. Available from: DOI: 10.1177/0269881115581093.
Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr 2013;11:82-99.
Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol 2023;11:474-89.
St-Onge MP, Cherta-Murillo A, Darimont C, Mantantzis K, Martin FP, Owen L. The interrelationship between sleep, diet, and glucose metabolism. Sleep Med Rev 2023;69:101788. Available from: doi: 10.1016/j.smrv.2023.101788.
Myers J, Kokkinos P, Nyelin E. Physical activity, cardiorespiratory fitness, and the metabolic syndrome. Nutrients 2019;11:1652. Available from: doi: 10.3390/nu11071652.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Salma Nazim, S Asha, Mili Babu (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
